Synlogic has announced it has secured $40 million in series B financing.
Synlogic, based in Cambridge, Mass., is a biopharmaceutical company focused on the development of a class of therapeutics, called synthetic biotics. Synlogic’s two lead therapeutic programs are being developed for the potential treatment of rare inborn errors of metabolism of Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
The financing round was led by OrbiMed HealthCare Fund Management. Deerfield Management Company and founding investors Atlas Venture and New Enterprise Associates also participated in the financing.
Synlogic indicated the financing would, in part, go toward supporting development efforts of its UCD and PKU programs, which the company said it plans to advance to the clinic in early 2017.